DK1663141T3 - Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin - Google Patents

Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin

Info

Publication number
DK1663141T3
DK1663141T3 DK04740995T DK04740995T DK1663141T3 DK 1663141 T3 DK1663141 T3 DK 1663141T3 DK 04740995 T DK04740995 T DK 04740995T DK 04740995 T DK04740995 T DK 04740995T DK 1663141 T3 DK1663141 T3 DK 1663141T3
Authority
DK
Denmark
Prior art keywords
xylometazoline
solution containing
aqueous pharmaceutical
pharmaceutical solution
oxymetazoline
Prior art date
Application number
DK04740995T
Other languages
Danish (da)
English (en)
Inventor
Frank Boehme
Bernd Eschenbach
Dagmar Faerber
Claudia Hey
Barbara Pfaff
Marion Tschaikin
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1663141(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1663141T3 publication Critical patent/DK1663141T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04740995T 2003-08-13 2004-07-14 Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin DK1663141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10337186A DE10337186A1 (de) 2003-08-13 2003-08-13 Wässrige Wirkstoff-Lösung
PCT/EP2004/007780 WO2005018601A1 (fr) 2003-08-13 2004-07-14 Solution pharmaceutique aqueuse contenant de l'oxymetazoline et/ou de la xylometazoline

Publications (1)

Publication Number Publication Date
DK1663141T3 true DK1663141T3 (da) 2007-07-30

Family

ID=34201503

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04740995T DK1663141T3 (da) 2003-08-13 2004-07-14 Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin

Country Status (19)

Country Link
US (1) US20060222718A1 (fr)
EP (1) EP1663141B1 (fr)
JP (1) JP4750703B2 (fr)
KR (1) KR20060065677A (fr)
CN (1) CN100531733C (fr)
AT (1) ATE357212T1 (fr)
AU (1) AU2004266443A1 (fr)
BR (1) BRPI0413478A (fr)
CA (1) CA2535533C (fr)
CY (1) CY1107633T1 (fr)
DE (2) DE10337186A1 (fr)
DK (1) DK1663141T3 (fr)
ES (1) ES2282871T3 (fr)
MX (1) MXPA06001596A (fr)
PL (1) PL1663141T3 (fr)
PT (1) PT1663141E (fr)
RU (1) RU2343918C2 (fr)
WO (1) WO2005018601A1 (fr)
ZA (1) ZA200602071B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE102007052380A1 (de) † 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
CN101576539B (zh) * 2009-06-19 2012-05-23 广东省药品检验所 一种盐酸赛洛唑啉中杂质a的测定方法
DE102012005452A1 (de) * 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CA2972177A1 (fr) 2014-12-24 2016-06-30 Jadran - Galenski Laboratorij D.D. Composition nasale contenant de l'eau de mer en tant qu'excipient d'amelioration de stabilite
JP6975473B2 (ja) * 2016-05-17 2021-12-01 プロポーネント バイオテック ゲーエムベーハー 鼻詰まりを治療／予防するためのカルボン酸
DE202017104738U1 (de) 2017-07-31 2018-08-01 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
CN107362141B (zh) * 2017-08-16 2018-06-05 深圳大佛药业股份有限公司 一种盐酸羟甲唑啉鼻喷雾剂及其制备方法
US20210244710A1 (en) * 2018-07-02 2021-08-12 Kangping Xiao Stable pharmaceutical formulations of oxymetazoline
US10799481B1 (en) * 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
WO2023046590A1 (fr) 2021-09-22 2023-03-30 Jadran - Galenski Laboratorij D.D. Composition pharmaceutique améliorée pour utilisation nasale, préparation et utilisation de celle-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
CA2311530C (fr) * 1998-01-30 2008-06-10 Novartis Consumer Health S.A. Preparations pharmaceutiques
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
CZ295595B6 (cs) * 1999-06-22 2005-08-17 Boehringer Ingelheim International Gmbh Stálý roztok xylometazolinu a oxymetazolinu
WO2002024116A1 (fr) * 2000-09-20 2002-03-28 Shahinian, Lee, Jr. Préparations et médications nasales, inhalables et ophtalmiques locales à conservation spontanée

Also Published As

Publication number Publication date
RU2006107446A (ru) 2007-09-20
MXPA06001596A (es) 2006-05-19
CN100531733C (zh) 2009-08-26
RU2343918C2 (ru) 2009-01-20
DE502004003305D1 (de) 2007-05-03
ES2282871T3 (es) 2007-10-16
AU2004266443A1 (en) 2005-03-03
CA2535533A1 (fr) 2005-03-03
JP2007501817A (ja) 2007-02-01
KR20060065677A (ko) 2006-06-14
BRPI0413478A (pt) 2006-10-17
EP1663141A1 (fr) 2006-06-07
JP4750703B2 (ja) 2011-08-17
PL1663141T3 (pl) 2007-07-31
DE10337186A1 (de) 2005-03-17
CY1107633T1 (el) 2013-03-13
ATE357212T1 (de) 2007-04-15
WO2005018601A1 (fr) 2005-03-03
EP1663141B1 (fr) 2007-03-21
CN1832726A (zh) 2006-09-13
PT1663141E (pt) 2007-06-27
CA2535533C (fr) 2011-10-18
ZA200602071B (en) 2007-05-30
US20060222718A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CY1107633T1 (el) Υδατικο φαρμακευτικο διαλυμα περιεχον οξυμεταζολινη και/ή ξυλομεταζολινη
NO20054018L (no) Intranasal formulering av rotigotin
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CU23367A3 (es) Formulación de moxifloxacino con sal común
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
NO20054848L (no) Substituerte p-diaminobenzenderivater
EA200602092A1 (ru) Способ и композиция для лечения ринита
AR035266A1 (es) Solucion desinfectante basada en hipoclorito sodico y procedimiento para su preparacion
PT1556371E (pt) Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
UA113749C2 (xx) Композиція для назального застосування з покращеною стабільністю
EA200870546A1 (ru) Стабильные водные суспензии
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
NO20070250L (no) S-Tenatoprazol-natriummonohydratsalt og dennes anvendelse i form av en protonpumpe-inhibitor
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
NO20055882L (no) Farmasoytiske formuleringer omfattende amoksicillin og klavulanat
FR2883702B1 (fr) Concentre emulsifiable contenant du 2',4'-difluoro-2-(alpha, alpha-trifluoro-m-tolyloxy)-nicotinanilide et composition aqueuse obtenue par dilution du concentre
NO20060743L (no) Nasal farmasoytisk sammensetning av piribedil
NO20044769L (no) Behandling av smerte med ifendropil
ATE528003T1 (de) Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen
NO20050834L (no) Ny indolinforbindelse og medisinsk anvendelse derav
RU2004125211A (ru) Способ профилактики заболеваний птиц
EA200500538A1 (ru) Фармацевтическое средство для эндоназального применения при лечении болезней и нарушений нервной системы
ATE531427T1 (de) Bekämpfung von hi-virus infektionen mit durch hypochlorige säure oxidiertem menschlichem blutplasma
SE0401942D0 (sv) New antimicrobial peptide complexes
ECSP003603A (es) Formulacion de sal comun y moxifloxacina